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Background: Choroidal neovascularization during the active stage of Toxoplasma retinochoroiditis is an uncommon
clinical presentation. The authors retrospectively reviewed medical charts of patients with coexisting choroidal
neovascular membrane and active Toxoplasma retinochoroiditis.
Findings: Three patients presented with coexisting choroidal neovascular membrane and active Toxoplasma
retinochoroiditis. All lesions had adjacent subretinal hemorrhage. The diagnosis was confirmed based on clinical
presentation, fundus fluorescein angiography (FFA), and optical coherence tomography (OCT) findings. The patients
were managed with a combination of treatments including intravitreal injection of anti-vascular endothelial growth
factor (anti-VEGF), oral anti-Toxoplasma treatment, and oral corticosteroids. In all patients, the retinitis lesion resolved
in 6 weeks and the coexisting choroidal neovascular membrane resolved over 6 to 12 weeks.
Conclusions: Recurrences in Toxoplasma retinochoroiditis are common as satellite lesions adjacent to an old
atrophic scar. Coexisting choroidal neovascularization with active Toxoplasma retinochoroiditis is an important
presentation and should be suspected in the presence subretinal hemorrhage and managed with a combination of
anti-Toxoplasma treatment and intravitreal anti-VEGF.
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Background
Necrotizing retinochoroiditis caused by an obligate
intracellular parasite, Toxoplasma gondii, is a common
inflammatory lesion of the fundus accounting for up to
70 % of cases with retinochoroiditis [1, 2]. By virtue of
high affinity for neural tissue and retinal ganglion cells
[3], the T. gondii localizes in retina and causes recurring
ocular inflammation. Focal necrotizing retinitis adjacent
to old retinochoroidal scar is the characteristic lesion in
ocular toxoplasmosis. The diagnosis of ocular toxoplas-
mosis can be made on the basis of clinical findings alone
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provided the original work is properly creditedthe following three clinical presentations of active
toxoplasmic retinochoroiditis (which occurs due to in-
flammatory response to activation of congenital toxo-
plasmosis [5]):
1) Large destructive active retinitis with associated
vitritis (most common);
2) Punctate inner areas of retinitis with minimal
associated edema and vitreous reaction;
3) Deep retinal punctate lesions with subretinal
exudate (most unusual) associated with a minimal
amount of vitreous reaction and with turbid
subretinal fluid or blood.
When these lesions heal, they lead to scars with an atro-
phic, “punched out” appearance and variable pigmentaryicle distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
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clude secondary glaucoma, retinochoroidal vascular
anastomosis, capillary non-perfusion, branch retinal
artery and vein occlusion, choroidal neovasculariza-
tion, cystoid macular edema, and optic atrophy [6].
Choroidal neovascularization (CNV) developing at the
margins of the healed Toxoplasma scar lesion is an im-
portant cause of vision loss in young patients with
maculopathy [2]. The prevalence of choroidal neovas-
cular membrane (CNVM) in toxoplasmosis cases is re-
ported to be 2–19 % [7, 8] during the late stage of the
disease [9, 10]. CNV has been well reported to occur dur-
ing the stage of healed toxoplasmosis [2, 9]. However,
CNVM coexisting with active retinochoroiditis is uncom-
mon. We report the clinical presentation and manage-
ment of three such patients.
Case 1
A 15-year-old male patient presented with sudden onset
blurring of vision in his right eye for 2 days and in the left
eye for 2 years. His visual acuity at presentation in the right
eye was 20/50, N18, and in the left eye 9/200, N36. Anter-
ior segment findings were unremarkable. The right eye
showed 1+ vitreous cells and a yellow-white active retinitis
lesion (approximately 1 disc diameter, infero-temporal to
fovea) adjacent to an old pigmented scar, a portion ofFig. 1 At presentation—a Color fundus photo of the right eye of case 1 show
infero-temporal to fovea) adjacent to an old pigmented scar, a part of which
present at and inferior to the fovea along with macular thickening and subret
(horizontal) over the lesion shows an elevated foveal contour with increased r
weeks of follow up—c Color fundus picture shows healed, pigmented, and sc
shows reduced retinal thickness, distorted architecture of retinal layers tempo
restoration of the foveal contourwhich is embedded in the active lesion (Fig. 1). Coexisting
subretinal hemorrhage was present at and inferior to the
fovea along with macular thickening and subretinal fluid
at the posterior pole. The left eye fundus showed disc
pallor and a large (approximately 1.5 disc diameter in
size), punched out, hyperpigmented scar at the macula.
Fundus fluorescein angiography (FFA) and optical coher-
ence tomography (OCT) (Fig. 1) confirmed the presence
of a coexisting active lesion with classic choroidal neovas-
cular membrane in the right eye. A diagnosis of recurrent
Toxoplasma retinochoroiditis with active CNVM in the
right eye and a healed Toxoplasma scar in the left eye
was made. He was treated with an intravitreal injection
of anti-vascular endothelial growth factor (anti-VEGF)
(bevacizumab) along with oral anti-parasitic medication
(320 mg trimethoprim and 1600 mg sulfamethoxazo-
le—i.e., cotrimoxazole twice a day) along with anti-
inflammatory medication (oral prednisone 60 mg/day).
The visual acuity started improving within 1 week (right
eye visual acuity—20/25 at 1 week with reduced subretinal
fluid at macula). Cotrimoxazole was continued, and a dose
of oral prednisolone was tapered over 1 month to 10 mg/
day. Oral steroids were gradually tapered off while cotri-
moxazole was discontinued after 2 weeks. At 20 weeks,
the visual acuity was 20/20 with healing and scarring of
the chorioretinal lesion (Fig. 1).s a yellow-white active retinitis lesion (approximately 1 disc diameter,
is embedded in the active lesion. Coexisting subretinal hemorrhage was
inal fluid at the posterior pole. b Optical coherence tomography scan
etinal thickness, hyper-reflectivity, and pockets of subretinal fluid. At 20
arred lesion infero-temporal to fovea and d OCT scan over the lesion
ral to the fovea, reduced amount of subretinal fluid, and relative
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A 51-year-old female patient presented with diminution
of vision in the right eye for 7 months. Visual acuity at
presentation was 6/200 in the right eye and 20/20 in the
left eye. Anterior segment examination was unremark-
able. Fundus examination in the right eye showed min-
imal vitritis with a well-defined pigmented Toxoplasma
scar and a yellowish-white necrotizing retinitis lesion ad-
jacent to the scar with subretinal hemorrhage. FFA and
OCT confirmed the presence of coexisting CNVM and
active retinitis. She was treated with monthly injections
of intravitreal anti-VEGF (bevacizumab) for 3 months
along with an oral anti-Toxoplasma drug (cotrimoxa-
zole) and a tapering dosage of oral corticosteroids for
6 weeks. After 4 months, her visual acuity improved to
20/200 in the right eye with healed chorioretinal scar
with regression of CNVM.
Case 3
A 32-year-old female presented with gradual diminution
of vision in the left eye for 4 months. Visual acuity in
the left eye was 3/200. Anterior segment examination of
both eyes and fundus in the right eye was unremarkable.
Fundus of the left eye had minimal vitritis with a
yellowish-white retinitis lesion (at the posterior pole)
and subretinal hemorrhage adjacent to a long-standing
hyperpigmented scar (temporal to the fovea). FFA and
OCT confirmed the presence of coexisting CNVM and
active retinitis in the left eye. The left eye was treated
with intravitreal injection of anti-VEGF (bevacizumab),
oral anti-Toxoplasma drug (cotrimoxazole), and systemic
corticosteroids. Intravitreal injection of bevacizumab was
repeated at 1 month. The visual acuity improved to 20/
100 and subretinal fluid regressed with healing and scar-
ring of the retinitis lesion which remains stable at
2 months of follow-up.
Discussion
In 1977, Willerson et al. [11] reported the first case of
subretinal neovascularization in association with active
Toxoplasma retinochoroiditis. The pathogenesis of
CNVM during the active stage of Toxoplasma retino-
choroiditis is thought to occur by a break in Bruch’s
membrane and choriocapillaris [12] due to intense ret-
inal inflammation. Because of this lesion, impeded ret-
inal venous outflow may lead to active vasoproliferation
and retinochoroidal vascular anastomosis [13]. Friable
vascular channels may ultimately lead to formation of
CNVM. Fundus fluorescein angiography (FFA) and op-
tical coherence tomography (OCT) help in confirming
the presence of coexisting neovascular membrane and
active retinochoroiditis. Monnet et al. [14] described the
OCT features of active toxoplasmosis as the presence of
highly reflective intraretinal area corresponding with thearea of retinitis, a thickened posterior hyaloid, and a
shadow effect of the underlying choroidal tissue. CNVM
during the healed stage generally occurs at the edge of the
Toxoplasma scar [8]; while in the active stage, CNVM
may be seen anywhere in the active retinitis lesion.
Options to treat CNVM secondary to resolved Toxo-
plasma retinitis include observation, corticosteroids,
laser photocoagulation [15], photodynamic therapy
(PDT) [16], submacular surgery [17], and intravitreal
anti-VEGF agents [15, 18]. Management of CNVM in
cases of healed toxoplasmosis with anti-VEGFs has been
associated with reactivation of the retinochoroiditis le-
sion, so few authors do recommend concomitant use of
oral anti-Toxoplasma treatment as prophylaxis [19].
However, if the CNVM coexists with the active stage of
Toxoplasma retinochoroiditis, the combination therapy
(anti-VEGF and anti-Toxoplasma treatment) becomes
very important as the combined approach addresses
both the active Toxoplasma lesion and the CNVM, thus
achieving better anatomic and visual outcomes [20]. The
anti-VEGFs are also effective in the management of sub-
foveal or juxtafoveal neovascular membrane as they also
reduce the collateral tissue damage to neurosensory ret-
ina and choroid as is seen with PDT or laser photo-
coagulation or submacular surgery [20].
In conclusion, all three patients presented with coex-
isting CNVM with activation of retinochoroiditis. The
diagnosis was based on clinical evaluation, FFA, and
OCT. All three patients were promptly started on anti-
Toxoplasma medical treatment along with intravitreal
anti-VEGF injection guided by the clinical evaluation
and the imaging findings. The lesions healed with re-
gression of the neovascular membrane in all three pa-
tients with improvement in visual outcome and
remained stable during a follow-up period ranging
from 2 to 4 months.
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